S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
S&P 500   3,380.80 (+0.53%)
DOW   27,816.90 (+0.13%)
QQQ   282.25 (+1.59%)
AAPL   116.79 (+0.85%)
MSFT   212.46 (+1.01%)
FB   266.63 (+1.81%)
GOOGL   1,487.90 (+1.52%)
AMZN   3,221.26 (+2.30%)
TSLA   448.16 (+4.46%)
NVDA   544.58 (+0.62%)
BABA   290.05 (-1.34%)
CGC   14.20 (-0.84%)
MU   47.92 (+2.04%)
GE   6.24 (+0.16%)
AMD   84.86 (+3.50%)
T   28.49 (-0.07%)
F   6.75 (+1.35%)
ACB   4.67 (+0.43%)
GILD   63.32 (+0.21%)
NFLX   527.51 (+5.50%)
DIS   123.31 (-0.62%)
BA   167.86 (+1.57%)
BAC   24.10 (+0.04%)
Log in
NASDAQ:UBX

Unity Biotechnology Stock Forecast, Price & News

$3.42
-0.04 (-1.16 %)
(As of 10/1/2020 05:03 PM ET)
Add
Compare
Today's Range
$3.40
Now: $3.42
$3.55
50-Day Range
$2.94
MA: $4.33
$12.43
52-Week Range
$2.72
Now: $3.42
$15.44
Volume491,299 shs
Average Volume714,108 shs
Market Capitalization$177.98 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.08
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
Read More
Unity Biotechnology logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.66 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees94
Market Cap$177.98 million
Next Earnings Date11/4/2020 (Estimated)
OptionableNot Optionable
$3.42
-0.04 (-1.16 %)
(As of 10/1/2020 05:03 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock price been impacted by COVID-19?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UBX stock has decreased by 36.5% and is now trading at $3.42.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Unity Biotechnology?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Unity Biotechnology
.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Unity Biotechnology
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) posted its quarterly earnings data on Friday, July, 31st. The company reported ($0.38) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.13.
View Unity Biotechnology's earnings history
.

What price target have analysts set for UBX?

6 analysts have issued 1-year price targets for Unity Biotechnology's stock. Their forecasts range from $4.00 to $20.00. On average, they expect Unity Biotechnology's stock price to reach $7.00 in the next year. This suggests a possible upside of 104.7% from the stock's current price.
View analysts' price targets for Unity Biotechnology
.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 3,570,000 shares, a decline of 40.6% from the August 15th total of 6,010,000 shares. Based on an average trading volume of 1,470,000 shares, the short-interest ratio is presently 2.4 days. Currently, 12.8% of the shares of the stock are short sold.
View Unity Biotechnology's Short Interest
.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), NVIDIA (NVDA), Inseego (INSG), Advanced Micro Devices (AMD), Canopy Growth (CGC), Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Enphase Energy (ENPH), Opko Health (OPK) and Plug Power (PLUG).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
  • Mr. Robert C. Goeltz II, Chief Financial Officer (Age 47, Pay $577.3k)
  • Dr. Anirvan Ghosh, Director & CEO (Age 56)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $3.42.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $177.98 million. Unity Biotechnology employs 94 workers across the globe.

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.